SEC Form 4 · accession 0001209191-18-010428
Viridian Therapeutics, Inc.\DE · VRDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Stuart Marshall
Officer — President & CEO · Director
Period of report
Feb 13, 2018
Accepted (ET)
Feb 15, 2018 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590750
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 13, 2018 | M | 115,818 | $0.57 | A | 265,646 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.57 | Feb 13, 2018 | M | 115,818 | D | — | Jul 30, 2018 | Common Stock | 115,818 | 0 | D |
Explanation of responses
- F1This filing relates to the exercise of vested options to purchase the Issuer's common stock granted to the Reporting Person under one of the Issuer's equity incentive plans. None of the shares of common stock received upon exercise of the option were sold by the Reporting Person and all such shares are subject to a lock-up agreement between the Reporting Person and certain underwriters.
- F2The option is fully vested and exercisable. The option expires ten years after the date of grant.